An interventional study of Ambulant nurse-assisted administration of zoledronic acid and Usual care in Hip Fractures, Osteoporosis and Zoledronic Acid, sponsored by University Hospital, Akershus. Recruiting at 1 site in Norway. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2024-02-05.
Sponsored by University Hospital, Akershus · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Hip Fractures with a site in Norway — 4 open to participants now, 6 under way, none of them phase 3. Hip Fractures · Norway.
Among the 30 studies in Hip Fractures with a site in Norway, this one is the 13th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2024, is one of 20 with no phase, and was the 28th registered.
843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.
Browse Hip Fractures studies →4 of the 30 studies in Hip Fractures with a site in Norway are open now. Recruiting first, the newest first:
University of Southern California · Sites in Norway, United States, Canada and 2 more countries
Ages 60+
Helse Stavanger HF · Sites in Norway
Ages 65–120
Vestre Viken Hospital Trust · Sites in Norway
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.
This study: 75 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 200 is above the median of 86 across 534 interventional studies indexed under Hip Fractures.
Median enrollment 200 across the 25 interventional studies, 184 across the 5 observational. Of the 23 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 30 have an industry lead sponsor. The 10 most frequent:
University Hospital, Akershus is the lead sponsor of 125 studies on the registry; 27 are open to participants now.
University Hospital, Akershus has 3 studies filed under Hip Fractures — fewer than ten, so there is no comparison to draw.
1 of the studies in Hip Fractures with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04868305Helse Stavanger HFIntramedullary Nail Versus Hip Arthroplasty in Unstable Trochanteric Hip Fractures | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Hip Fractures with a site in Norway, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a study to improve the collaboration between primary and secondary health care on the treatment of osteoporosis after a hip fracture. In Akershus University Hospital, patients 75 years or older with a hip fracture, are offered treatment with an infusion of zoledronic acid 5mg, combined with vitamin D and calcium supplements, to prevent new fractures. General practitioners (GPs) are requested to take care of the follow-up on this treatment with annual infusions of zoledronic acid for 3 years.
In the opinion of the investigators, it is expedient, safe, and sensible for parts of the subsequent treatment to be provided by GPs. If hospitals take responsibility for initiating the treatment, the investigators believe that most of the subsequent monitoring and continuance of treatment can be conducted by the primary healthcare service. Despite this, the investigators suspect that many patients do not get their annual infusions of zoledronic acid after discharge from the hospital.
This quality assurance study aims to test a new system where ambulant nurses from the hospital support the GP in treating osteoporosis with the administration of zoledronic acid in the following 3 years after femoral neck fractures. Through the project, the investigators will create procedures for the administration and follow-up of zoledronic acid fitted in the setting of the GP office.
The design is a cluster randomized controlled study (RCT) where the regions are prospectively randomized to either intervention or control regions. Patients ≥ 75 years, which suffer a femoral neck fracture, are identified in our Department of Orthopedic Surgery, where they are provided the first infusion of zoledronic acid 5 mg and proposed participation in the study. Patients from the intervention regions will be followed by the protocol of ambulant nurse-assisted administration of zoledronic acid. Patients from the control regions are offered the usual care. Both patients from the control and intervention regions are asked to fill out a questionnaire after 1 year. The questionnaire will ask if the patient has got zoledronic acid as encouraged in the medical journal after discharge from the hospital. The primary study outcome is if the patients are offered treatment at a one-year follow-up or not.
Sample size calculation estimates a total sample of 130 patients based on a minimal clinically important difference of 20% follow-up between the groups. Because of high mortality, the investigators estimate the need for 200 patients.
The investigators hypothesize that the one-year follow-up is better in the intervention group than in the control group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients from the intervention regions will be followed the protocol of ambulant nurse-assisted administration of zoledronic acid
Procedure: Ambulant nurse-assisted administration of zoledronic acid
Patients from the control regions are followed as usual. General practitioners are requested to take care of the follow-up, through the patients and the discharge summary, with annual infusions of zoledronic acid.
Procedure: Usual care
Patients from the intervention regions will be followed by the protocol of ambulant nurse-assisted administration of zoledronic acid.
General practitioners are requested to take care of the follow-up, through the patients and the discharge summary, with annual infusions of zoledronic acid.
Number of participants offered treatment after one year
The primary study outcome is the number of participants offered treatment with zoledronic acid after one-year.
Time frame: One year
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Dec 2025, 23 months after the start.
Of 221 non-industry interventional studies with no phase under Hip Fractures, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 55. This study's planned 23 months is below that.
Counting every sponsor, half of 237 studies reached it within 29 months; a quarter within 10 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Akershus →